Oxytocin Administration in BDD and OCD
Condition: Body Dysmorphic Disorder; Obsessive-compulsive Disorder
MeSH terms: Compulsive Personality Disorder; Obsessive-Compulsive Disorder; Body Dysmorphic Disorders
Intervention: Oxytocin; Placebo
Intervention description: Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.; Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
Intervention MeSH terms: Oxytocin
Phase: Phase 2
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Enrollment: 41.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Oxytocin; Body dysmorphic disorder; Obsessive-compulsive disorder

Summary:

      The purpose of the current study is to investigate the effect of an acute administration of
      intranasal oxytocin, relative to placebo, on social cognitive impairments among individuals
      with body dysmorphic disorder and obsessive-compulsive disorder, compared to healthy
      controls.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Treatment-seeking adult males and females ≥ 18 years of age

          -  Meets DSM-IV criteria for principal BDD (for BDD group) or principal OCD (for OCD
             group), as determined by Structured Clinical Interview for DSM-IV (SCID) diagnostic
             interview

          -  For females only: must be taking low-dose oral contraceptive pills, as defined by
             monophasic pills containing <50 mcg ethinyl estradiol

          -  For healthy volunteers only: does not meet current DSM-IV diagnosis of any Axis I
             disorder

        Exclusion Criteria:

          -  Participants in the BDD group will be excluded if they have a comorbid diagnosis of
             OCD and participants in the OCD group will be excluded if they have a comorbid
             diagnosis of BDD.

          -  Current diagnosis of schizophrenia, psychotic disorder, bipolar disorder, substance
             abuse or substance dependence. All other Axis I comorbidities will be permitted to
             foster the accrual of a clinically relevant sample.

          -  Significant nasal pathology (e.g., atrophic rhinitis, history of hypophysectomy,
             recurrent nosebleeds)

          -  Smokers who smoke ≥ 15 cigarettes daily

          -  Serious medical illnesses

          -  Active homicidal or suicidal ideation

          -  Concurrent use of psychotropic medications

          -  Steroid or hormone use (except low-dose oral contraceptive pills for females, which is
             allowed)

          -  For females only: positive urine pregnancy test and use of high dose
             estrogen/progestin pills (low dose estrogen/progestin oral contraceptives will be
             allowed due to stability of hormone levels during active phase)

          -  For healthy volunteers only: any current DSM-IV Axis I disorder